ESMO 2023: Does stopping VEGFR TKI treatment and continuing immunotherapy influence the survival of patients on combination therapy?
In many countries, combinations of VEGFR TKI anti-cancer mediations plus [...]
In many countries, combinations of VEGFR TKI anti-cancer mediations plus [...]
A recent study published in the journal JAMA Oncology has [...]
Axitinib is a medicine for the treatment of advanced kidney [...]
This study looked at the incidence, diagnosis and treatment of [...]
This programme of 11 webinars involves a kidney cancer patient, [...]
At the International Kidney Cancer Symposium (IKCS) in the USA [...]
The following presentations from the Educated Patient® Kidney Cancer Summit [...]
Immunotherapy has changed the way advanced renal cell carcinoma (RCC) [...]
Treatment of people with intermediate to high risk renal cell [...]
A recent study published in Journal of Clinical Medicine this [...]